UnitedHealth Group Shares Drop Amid DOJ Fraud Investigation

Shares of UnitedHealth Group (NYSE: UNH) are experiencing significant declines on Thursday. The stock has tumbled 15% as of 11:33 a.m. ET and saw a peak drop of 19.2% earlier in the day. This stark decline comes while the S&P 500 has gained 0.1% and the Nasdaq Composite has dropped 0.4%.

Ongoing Investigation into Medicare Fraud

Reports indicate that the Department of Justice (DOJ) is investigating UnitedHealth for potential Medicare fraud. According to a report from The Wall Street Journal, the DOJ’s healthcare fraud unit has been probing this issue since at least last summer.

UnitedHealth was reportedly unaware of the investigation until the news went public. Following the disclosure, the company affirmed its commitment to the integrity of its Medicare Advantage program.

Additional Concerns for the Company

This investigation is not the only challenge facing UnitedHealth. It is also involved in a civil fraud case related to its Medicare billing practices. Compounding these troubles, the company’s CEO, Andrew Witty, left unexpectedly for personal reasons just days prior to the news of the new investigation.

Image source: Getty Images.

Financial Pressures Impacting UnitedHealth

UnitedHealth is facing escalating health costs that are squeezing its profit margins. The company had to lower its full-year guidance during its last quarterly earnings report. These issues have shaken investor confidence, leading to a staggering 50% drop in shares over just 23 trading days. This decline marks the most significant drop for an S&P 100 company since Netflix fell 54% in May 2022, according to Dow Jones Market Data.

Given the multitude of challenges, UnitedHealth once appeared stable, but now presents a risky investment opportunity.

Investment Considerations for UnitedHealth Group

Before deciding to invest in UnitedHealth Group, consider the following:

The Motley Fool analyst team has highlighted other stocks as more favorable investment choices right now. UnitedHealth Group did not make their list of the top ten stocks to buy.

Conclusion

Given the recent performance and ongoing investigations, potential investors should exercise caution regarding UnitedHealth Group. It may be prudent to monitor the situation closely before making any investment decisions.

The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.